Circio Holding ASA (CRNA) - Total Liabilities
Based on the latest financial reports, Circio Holding ASA (CRNA) has total liabilities worth Nkr25.15 Million NOK (≈ $2.65 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Circio Holding ASA cash flow conversion to assess how effectively this company generates cash.
Circio Holding ASA - Total Liabilities Trend (2020–2024)
This chart illustrates how Circio Holding ASA's total liabilities have evolved over time, based on quarterly financial data. Check CRNA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Circio Holding ASA Competitors by Total Liabilities
The table below lists competitors of Circio Holding ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Binh Dien Fertilizer JSC
VN:BFC
|
Vietnam | ₫2.27 Trillion |
|
Entech SE SAS
PA:ALESE
|
France | €49.43 Million |
|
Source Energy Services Ltd
TO:SHLE
|
Canada | CA$387.55 Million |
|
Dongsung Corporation
KO:102260
|
Korea | ₩473.68 Billion |
|
SSH Communications Security Oyj
HE:SSH1V
|
Finland | €17.20 Million |
|
Gordon Auto Body Parts Co Ltd
TW:1524
|
Taiwan | NT$2.26 Billion |
|
Gabelli MultiMedia Mutual Fund
NYSE:GGT
|
USA | $448.92K |
|
Douglas Elliman Inc
NYSE:DOUG
|
USA | $261.13 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Circio Holding ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Circio Holding ASA market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.25 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Circio Holding ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Circio Holding ASA (2020–2024)
The table below shows the annual total liabilities of Circio Holding ASA from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr34.34 Million ≈ $3.61 Million |
-72.36% |
| 2023-12-31 | Nkr124.25 Million ≈ $13.07 Million |
+26.99% |
| 2022-12-31 | Nkr97.85 Million ≈ $10.30 Million |
-33.68% |
| 2021-12-31 | Nkr147.54 Million ≈ $15.53 Million |
-0.41% |
| 2020-12-31 | Nkr148.15 Million ≈ $15.59 Million |
-- |
About Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a … Read more